Pernix Therapeutics
Manufacturer Details
There are currently no manufacturer details available.
Pernix Therapeutics Drugs
-
![Z-cof 12 Dm (Pseudoephedrine Hydrochloride, Guaifenesin, And Dextromethorphan Hydrobromide) Liquid [Pernix Therapeutics]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ecbd09eb-3789-4c66-b62d-8bd2228413b9&name=z-cof-01.jpg)
Z-cof 12 Dm
Do not exceed recommended dosage.
Adults and children 12 years of age and older: 2 teaspoonfuls (10 mL) every 8 hours, not to exceed 6 teaspoonfuls in 24 hours Children 6 to under 12 years of age: 1 teaspoonful (5 mL) every 8 hours, not to exceed 3 teaspoonfuls in 24 hours Children under 6 years of age: Consult a doctor -
![Methylphenidate Hydrochloride Tablet, Extended Release [Kremers Urban Pharmaceuticals Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=67311f35-35cc-469d-a6eb-cf615af5403a&name=treximet-05.jpg)
Methylphenidate Hydrochloride
2.1 Dosage in Adults
The recommended dosage for adults is 1 tablet of TREXIMET 85/500 mg. TREXIMET 85/500 mg contains a dose of sumatriptan higher than the lowest effective dose. The choice of the dose of sumatriptan, and of the use of a fixed combination such as in TREXIMET 85/500 mg should be made on an individual basis, weighing the possible benefit of a higher dose of sumatriptan with the potential for a greater risk of adverse reactions.
The maximum recommended dosage in a 24-hour period is 2 tablets, taken at least 2 hours apart.
The safety of treating an average of more than 5 migraine headaches in adults in a 30-day period has not been established.
2.2 Dosage in Pediatric Patients 12 to 17 Years of Age
The recommended dosage for pediatric patients 12 to 17 years of age is 1 tablet of TREXIMET 10/60 mg.
The maximum recommended dosage in a 24-hour period is 1 tablet of TREXIMET 85/500 mg.
The safety of treating an average of more than 2 migraine headaches in pediatric patients in a 30-day period has not been established.
2.3 Dosing in Patients with Hepatic Impairment
TREXIMET is contraindicated in patients with severe hepatic impairment [see Contraindications (4), Use in Specific Populations (8.7), Clinical Pharmacology (12.3)].
In patients with mild to moderate hepatic impairment, the recommended dosage in a 24-hour period is 1 tablet of TREXIMET 10/60 mg [see Use in Specific Populations (8.7), Clinical Pharmacology (12.3)].
2.4 Administration Information
TREXIMET may be administered with or without food. Tablets should not be split, crushed, or chewed.
-
![Khedezla Extended-release (Desvenlafaxine) Tablet, Extended Release [Pernix Therapeutics]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=130b1f08-7b46-4f72-b3ff-03812687d8ce&name=khedezla-2.jpg)
Khedezla Extended-release
2.1 General Instruction for Use
The recommended dose for KHEDEZLA is 50 mg once daily, with or without food.
In clinical studies, doses of 50 mg to 400 mg per day were shown to be effective, although no additional benefit was demonstrated at doses greater than 50 mg per day and adverse reactions and discontinuations were more frequent at higher doses.
When discontinuing therapy, gradual dose reduction is recommended whenever possible to minimize discontinuation symptoms [see Dosage and Administration (2.4 ) and Warnings and Precautions (5.7 )].
KHEDEZLA should be taken at approximately the same time each day. Tablets must be swallowed whole with fluid and not divided, crushed, chewed, or dissolved.
2.2 Special Populations
Patients with renal impairment
The maximum recommended dose in patients with moderate renal impairment (24-hr creatinine clearance [CrCl] = 30 to 50 mL/min, Cockcroft-Gault [C-G]) is 50 mg per day. The maximum recommended dose in patients with severe renal impairment (24-hr CrCl less than 30 mL/min, C-G) or end-stage renal disease (ESRD) is 50 mg every other day. Supplemental doses should not be given to patients after dialysis [see Use in Specific Populations (8.6 ) and Clinical Pharmacology (12.3 .)].
Patients with hepatic impairment
The recommended dose in patients with moderate to severe hepatic impairment is 50 mg per day. Dose escalation above 100 mg per day is not recommended [see Clinical Pharmacology (12.3 )].
2.3 Maintenance/Continuation/Extended Treatment
It is generally agreed that acute episodes of major depressive disorder require several months or longer of sustained pharmacologic therapy. Patients should be periodically reassessed to determine the need for continued treatment.
2.4 Discontinuing KHEDEZLA
Symptoms associated with discontinuation of KHEDEZLA, other SNRIs and SSRIs have been reported [see Warnings and Precautions (5.7 )]. Patients should be monitored for these symptoms when discontinuing treatment. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose, but at a more gradual rate.
2.5 Switching Patients From Other Antidepressants to KHEDEZLA
Discontinuation symptoms have been reported when switching patients from other antidepressants, including venlafaxine, to desvenlafaxine. Tapering of the initial antidepressant may be necessary to minimize discontinuation symptoms.
2.6 Switching Patients To or From a Monoamine Oxidase Inhibitor (MAOI) Intended to Treat Psychiatric Disorders
At least 14 days should elapse between discontinuation of an MAOI intended to treat psychiatric disorders and initiation of therapy with KHEDEZLA. Conversely, at least 7 days should be allowed after stopping KHEDEZLA before starting an MAOI intended to treat psychiatric disorders [see Contraindications (4)].
Use of KHEDEZLA with other MAOIs such as Linezolid or Methylene Blue
Do not start KHEDEZLA in a patient who is being treated with linezolid or intravenous methylene blue because there is increased risk of serotonin syndrome. In a patient who requires more urgent treatment of a psychiatric condition, other interventions, including hospitalization, should be considered [see Contraindications (4)] .
In some cases, a patient already receiving KHEDEZLA therapy may require urgent treatment with linezolid or intravenous methylene blue. If acceptable alternatives to linezolid or intravenous methylene blue treatment are not available and the potential benefits of linezolid or intravenous methylene blue treatment are judged to outweigh the risks of serotonin syndrome in a particular patient, KHEDEZLA should be stopped promptly, and linezolid or intravenous methylene blue can be administered. The patient should be monitored for symptoms of serotonin syndrome for 7 days or until 24 hours after the last dose of linezolid or intravenous methylene blue, whichever comes first. Therapy with KHEDEZLA may be resumed 24 hours after the last dose of linezolid or intravenous methylene blue [see Warnings and Precautions (5.2 )].
The risk of administering methylene blue by non-intravenous routes (such as oral tablets or by local injection) or in intravenous doses much lower than 1 mg/kg with KHEDEZLA is unclear. The clinician should, nevertheless, be aware of the possibility of emergent symptoms of serotonin syndrome with such use [see Warnings and Precautions (5.2 )].
Sign Up for a Free Account